Why Do Some Cancers Not Respond to Chemotherapy?

Some tumours block chemotherapy before it can act. They pump the drug out, repair the DNA damage it causes, or simply lack the receptor it needs to get inside the cell. Others start sensitive and turn resistant mid-treatment as surviving cells take over. This isn’t a dosing problem or a clinical error. It’s tumour biology, and most of it shows up in molecular profiling before the first cycle begins. When chemo stops working, targeted therapy or immunotherapy is usually what comes next.

According to Dr. Sandeep Nayak, Best cancer treatment in Bangalore, “Chemotherapy resistance is one of the most misunderstood aspects of cancer treatment. It’s not that the drugs are weak or the dose was wrong. The tumour’s molecular biology decides whether chemotherapy reaches its target and whether that target is still vulnerable when it gets there.”

Resistance isn’t random. It runs through specific biological mechanisms, and each one points to a different next step.

• Drug Efflux Pumps: Certain cancer cells carry proteins that push chemotherapy back out before it does anything. Higher doses don’t fix this. The pump runs harder under higher concentrations.
• DNA Repair Upregulation: Chemo works by damaging DNA. Some tumours repair that damage faster than the drug creates it. BRCA proficient tumours resist platinum this way. Drug lands, cell fixes it, nothing dies.
• Tumour Heterogeneity: One tumour holds multiple cell populations with different genetics. Chemo clears the sensitive ones first. What’s left are the resistant cells and with no competition, they take over. What grows back isn’t the same tumour that was there before.
• Reduced Drug Uptake: Some cells lose the receptors that let chemotherapy inside. The drug circulates in the blood and never enters where it needs to work. No entry, no effect, regardless of dose.

The molecular profile drives these differences far more than the cancer type does. Precision Oncology testing maps resistance markers before treatment starts so the right drug gets chosen from the beginning, not discovered after three failed cycles.

Resistance redirects treatment. It doesn’t end it.

• Targeted Therapy: Molecular profiling finds driver mutations like EGFR, HER2, or BRAF. Targeted drugs block that specific pathway regardless of chemo history. Sensitivity to targeted therapy and chemo resistance are separate properties. They don’t predict each other.
• Immunotherapy: Tumours with high mutational burden or MSI-high status can respond well to checkpoint inhibitors even after chemo has failed completely. Immunotherapy runs on a different mechanism. What happened with chemo says nothing about how the tumour will respond to it.
• Switching Drug Classes: Platinum resistant tumours may still respond to taxane or fluoropyrimidine regimens. Different mechanism means different vulnerability. Resistance to one class isn’t resistance to all of them.
• Clinical Trials: Patients with confirmed chemo resistant disease often qualify for trials targeting resistance pathways directly. New resistance mechanisms get their first matched treatments through trials before reaching standard practice.

For more on what happens when patients stop chemotherapy and what the consequences look like clinically, our previous blog on Refuse Chemotherapy covers the outcomes behind that decision.

Dr. Sandeep Nayak’s team at MACS Clinic profiles every tumour before chemotherapy begins. Resistance markers get mapped upfront so the drug chosen in cycle one matches what the tumour’s biology will actually respond to. Tumour board review combines pathology, molecular data, and oncology input before any plan is confirmed.

Patient here doesn’t spend three cycles on a regimen the biopsy would have ruled out from the start. Molecular data decides the drug. Not the diagnosis name.

Call +91 8035740000 to book your consultation.

References

1. Chemotherapy resistance mechanisms — National Cancer Institute
2. Cancer drug resistance — World Health Organization